Serum TGF- β 1 and CD14 Predicts Response to Anti-TNF- α Therapy in IBD
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F23%3A00573773" target="_blank" >RIV/61388971:_____/23:00573773 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10465723 RIV/00216208:11310/23:10465723 RIV/00216208:11110/23:10465723 RIV/00064211:_____/23:W0000016 RIV/00023001:_____/23:00083994
Result on the web
<a href="https://www.hindawi.com/journals/jir/2023/1535484/" target="_blank" >https://www.hindawi.com/journals/jir/2023/1535484/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1155/2023/1535484" target="_blank" >10.1155/2023/1535484</a>
Alternative languages
Result language
angličtina
Original language name
Serum TGF- β 1 and CD14 Predicts Response to Anti-TNF- α Therapy in IBD
Original language description
Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which delays efficient control of the intestinal inflammation. Methods. We analyzed the power of serum biomarkers to predict the failure of anti-TNF-α. We collected serum of 38 IBD patients at therapy prescription and 38 weeks later and analyzed them with relation to therapy response (no-, partial-, and full response). We used enzyme-linked immunosorbent assay to quantify 16 biomarkers related to gut barrier (intestinal fatty acid-binding protein, liver fatty acid-binding protein, trefoil factor 3, and interleukin (IL)-33), microbial translocation, immune system regulation (TNF-α, CD14, lipopolysaccharide-binding protein, mannan-binding lectin, IL-18, transforming growth factor-β1 (TGF-β1), osteoprotegerin (OPG), insulin-like growth factor 2 (IGF-2), endocrine-gland-derived vascular endothelial growth factor), and matrix metalloproteinase system (MMP-9, MMP-14, and tissue inhibitors of metalloproteinase-1). Results. We found that future full-responders have different biomarker profiles than non-responders, while partial-responders cannot be distinguished from either group. When future non-responders were compared to responders, their baseline contained significantly more TGF-β1, less CD14, and increased level of MMP-9, and concentration of these factors could predict non-responders with high accuracy (AUC = 0.938). Interestingly, during the 38 weeks, levels of MMP-9 decreased in all patients, irrespective of the outcome, while OPG, IGF-2, and TGF-β1 were higher in non-responders compared to full-responders both at the beginning and the end of the treatment. Conclusions. The TGF-β1 and CD14 can distinguish non-responders from responders. The changes in biomarker dynamics during the therapy suggest that growth factors (such as OPG, IGF-2, and TGF-β) are not markedly influenced by the treatment and that anti-TNF-α therapy decreases MMP-9 without influencing the treatment outcome.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Immunology Research
ISSN
2314-8861
e-ISSN
2314-7156
Volume of the periodical
2023
Issue of the periodical within the volume
20 June 2023
Country of publishing house
GB - UNITED KINGDOM
Number of pages
16
Pages from-to
1535484
UT code for WoS article
001020096700002
EID of the result in the Scopus database
2-s2.0-85164231091